<DOC>
	<DOCNO>NCT00043940</DOCNO>
	<brief_summary>Primary Objective : To assess safety bivalirudin alternative anticoagulant therapy patient new previous heparin-induced thrombocytopenia ( HIT ) / heparin-induced thrombocytopenia thrombosis syndrome ( HITTS ) undergo percutaneous coronary intervention ( PCI ) . This measure composite incidence major bleed event administration within 48 hour stop bivalirudin ( hospital discharge , whichever occur first ) . The component composite endpoint : ) intracranial bleeding ; b ) retroperitoneal bleeding ; c ) bleeding result hemodynamic compromise ; ) bleeding require transfusion three unit whole blood pack red cell ; e ) decrease hemoglobin great equal g/dL hematocrit great equal 9 % . Secondary Objectives : Each component primary composite endpoint . To evaluate level anticoagulation achieve bivalirudin . The goal achieve activate clotting time ( ACT ) 300 350 sec PCI 4-hour bivalirudin infusion . To evaluate bivalirudin 's effect platelet count .</brief_summary>
	<brief_title>Anticoagulant Therapy With Bivalirudin Performance Percutaneous Coronary Intervention Patients With Heparin-Induced Thrombocytopenia ( AT BAT , First Inning )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>INCLUSION : Males female least 18 year age , Be able provide write informed consent , Need anticoagulation percutaneous coronary intervention ( angioplasty , rotational atherectomy , directional coronary atherectomy , transluminal extraction catheter , coronary stent ) , New diagnosis history clinically suspect objectively document HIT/HITTS , define : ( A ) Positive heparininduced platelet aggregation ( HIPA ) functional assay , define : ( B ) HIT : Thrombocytopenia associate heparin therapy , platelet count : ( ) decrease &lt; 100x10 ( 9 ) /L ( minimum 30 % drop platelet count heparin treatment ) , OR ( ii ) decrease &lt; 150x10 ( 9 ) /L ( minimum 40 % drop platelet count heparin treatment , OR , ( C ) HITTS : Thrombocytopenia ( define ) PLUS arterial venous thrombosis ( deepvein thrombosis , pulmonary embolism , mesenteric venous arterial thrombosis , acute myocardial infarction , leave ventricular thrombus , ischemic stroke , occlusion limb artery ) , diagnose physical exam/lab evidence and/or appropriate imaging study ( duplex ultrasound , venography , ventilationperfusion scan , venous arterial angiography , MRI/MRA , catheterization ) . EXCLUSION : Overt known active significant bleeding , Definitive evidence alternative explanation thrombocytopenia ( e.g.m DIC , sepsis , consumptive coagulopathy , ITP , TTP , HUS , bonemarrow failure ) , Coagulation disorder bleed diathesis unrelated HIT/HITTS , Patients renal impairment , define calculated creatinine clearance &lt; 30 mL/min , medical condition ( include hepatic , pulmonary , gastrointestinal , endocrine , psychiatric ) , investigator 's opinion , would endanger patient she/he receives anticoagulant therapy , Nonhemorrhagic stroke within past 6 month previous hemorrhagic stroke , Intracranial neoplasm , cerebral/spinal arteriovenous malformation aneurysm , Lumbar puncture , spinal/epidural catheter placement within past 7 day , Known prior hemorrhage ( gastrointestinal , genitourinary , pericardium , pleural , retroperitoneal space ) , major surgery , serious trauma within past 6 week , unless attend physician believe need anticoagulation PCI outweigh potential bleeding risk , Puncture noncompressible vessel within 24 hour plan PCI , Confirmed uncontrolled hypertension ( systolic blood pressure &gt; = 100 mmHg ) study entry , Ongoing anticoagulant therapy study entry . However , patient may enter therapy safely stop periprocedurally , , case oral warfarin , prothrombin time INR safely bring &lt; = 1.5 study drug infusion , Known suspect pregnancy , breastfeed . Women childbearing potential must negative pregnancy test ( urine blood ) must make explicitly aware bivalirudin may cause excessive menstrual bleeding . Known suspected pregnancy , breastfeeding , Known hypersensitivity bivalirudin leech protein , If patient participate drug trial within past 48 hour , call DCRI hotline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>thrombosis</keyword>
	<keyword>bivalirudin</keyword>
	<keyword>direct thrombin inhibitor</keyword>
	<keyword>HIT</keyword>
	<keyword>HITTS</keyword>
	<keyword>HIT/HITTS</keyword>
</DOC>